Skip to contentO
OptimizeRx Corp
O
OPRXOptimizeRx Corp Q4 2013 · 10-K
derived · Computed from the longer spans the company filed.
Revenue$1.25M$1.25Mderived+80.3% vs Q4 2012 Net Income$392.63K$392.63Kderived+1,281.7% vs Q4 2012 EPS, diluted—Not derived. Share counts vary by quarter.
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
OptimizeRx Corp · CIK 1448431 · Engraved from SEC EDGAR
Gross Profitderived$936,077— Operating Incomederived-$579,875N/M Operating Cash Flowderived$829,641+50,704.7% Free Cash Flowderived$829,641+50,704.7% Margins · derivedGross margin75.1%
Operating margin-46.5%−50.6 pt vs Q4 2012
Net margin31.5%+27.4 pt vs Q4 2012
ended Dec 31, 2013 · filed Mar 31, 2014 · 90 d after period end